Stockwinners Market Radar for March 25, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Less than half of Americans trust Facebook (FB) to obey U.S. privacy laws, according to Reuters, citing a Reuters/Ipsos poll illustrating the challenge facing the social media network after a scandal over its handling of personal information. The poll also found that fewer Americans trust Facebook than other tech companies that gather user data, such as Apple (AAPL), Google (GOOGL, GOOG), Amazon (AMZN), or Microsoft (MSFT), the report added. 2. Tesla (TSLA) has been instructed to "slow down" on car deliveries in Norway this quarter, CEO Elon Musk said, in response to woes it has experienced delivering vehicles, according to CNBC. 3. In its cover story titled "Facebook Comes Under Siege," Barron's said Facebook shares may be more tempting to investors following last week's 14% decline. With more than 2B users, however, Facebook is "almost certain" to not walk away unscathed as the top target for privacy concerns, Jon Swartz wrote. Nonetheless, with nearly $42B in cash and investments, Facebook has the flexibility to diversify into other business lines, as it did with Instagram and WhatsApp, Swartz added. 4. Comcast (CMCSA, CMCSK) subsidiary Universal's "Pacific Rim: Uprising," the sequel to 2013 science fiction action film "Pacific Rim," debuted at number one, with $28M from 2,850 theaters. The film scored 47% from Rotten Tomatoes and got a B CinemaScore from movie audiences. 5. Interactive Borkers (IBKR) and Time Warner (TWX) saw positive mentions in Barron's.

16:25 EDT Box Office Battle: 'Pacific Rim: Uprising' beats 'Black Panther' - Comcast (CMCSA, CMCSK) subsidiary Universal's "Pacific Rim: Uprising," the sequel to 2013 science fiction action film "Pacific Rim," debuted at number one, with $28M from 2,850 theaters. The film scored 47% from Rotten Tomatoes and got a B CinemaScore from movie audiences. BOX OFFICE RUNNERS-UP: Disney (DIS) and Marvel Studios' "Black Panther" fell to second place in its sixth weekend, banking another $16.7M for a domestic total of $630.9M and becoming the top-grossing superhero film of all time in North America and the number 5 title of all time, adjusted for inflation. Behind it was Roadside Attractions and Lionsgate's (LGF.A) "I Can Only Imagine," which fell 19% to an estimated $14M for a 10-day domestic total of $38.5M. Viacom (VIA, VIAB) subsidiary Paramount's animated "Sherlock Gnomes" debuted at number four, with just $10.6M from 3,663 theaters. Rounding out the top five, Warner Bros.' (TWX) "Tomb Raider" earned an estimated $10.4M for a 10-day North America total of $41.7M. Other publicly traded companies in filmmaking include 21st Century Fox's (FOXA), and Sony's (SNE).

08:14 EDT ImmunoGen presents data from FORWARD II assessment of Mirvetuximab Soravtansine - ImmunoGen (IMGN) announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck's (MRK) anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer. In the subset of 8 patients with medium or high folate receptor alpha expression levels, the confirmed overall response rate was 63%, with a median progression-free survival of 8.6 months. For all patients, the confirmed ORR was 43%, with a median PFS of 5.2 months; patients in this cohort had received a median of 4.5 prior lines of systemic therapy, with 64% of patients receiving 4 or more prior lines. As previously reported, at full dosing, the combination of mirvetuximab and pembrolizumab demonstrates favorable tolerability, consistent with the known safety profiles of each agent, with primarily mild to moderate adverse events observed. Based on these data, ImmunoGen is enrolling an additional 35 patients with medium or high FRalpha expression levels in an expansion cohort in the FORWARD II study.